{"id":845943,"date":"2025-05-02T08:04:42","date_gmt":"2025-05-02T12:04:42","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/"},"modified":"2025-05-02T08:04:42","modified_gmt":"2025-05-02T12:04:42","slug":"alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/","title":{"rendered":"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., May  02, 2025  (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open.<\/p>\n<p>The company will not be hosting a teleconference in conjunction with its financial results press release.<\/p>\n<p>\n        <strong>About ALX Oncology<\/strong><br \/>\n        <br \/>ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology\u2019s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action and is anticipated to enter Phase 1 trials mid-2025. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=M7Iz8UONdWknftf7M8IessjMC9IDTGtSYIQ8oB2Yc5mNE4VC9aNNHiCiRIc-_RxvrvvOTbyNObEm8DFyRWopRl7QSdJKb3mHQxzXkVXcRGw=\" rel=\"nofollow\" target=\"_blank\"><u>www.alxoncology.com<\/u><\/a> and on LinkedIn <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u-O5VlcuutaLIoWd9BvviHH9NrZrcZ9_kviDOtO279OnOzV7HS_Lc7RdVz6IxKRSQjTWilyxpxid33a7oXxbzrfl1OSsekwKWUdrpwxVKUKreLaeXBb6O-bd1fkUoh3hPp_s8CX3U9Uc7dHxHiElew==\" rel=\"nofollow\" target=\"_blank\"><u>@ALX Oncology<\/u><\/a>.<\/p>\n<p>\n        <strong>Investor Relations Contact:<\/strong><br \/>\n        <br \/>Elhan Webb, CFA, IR Consultant<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BWk1Pbu6ablY94U2fOEPKhsmgmyIc-GvrMhVqhGtkcUBxiUwMrAD1uOIeypr046vmppefeH59cYU3VvSROT07DxIgMaI7QZ9ew-BeeHxh48=\" rel=\"nofollow\" target=\"_blank\"><u>ewebb@alxoncology.com<\/u><\/a><\/p>\n<p>\n        <strong>Media Contact: <\/strong><br \/>\n        <br \/>Audra Friis, Sam Brown, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q-DwigPM5_W4sIEswVWJXS2obQGmixiB27hYZgoWdwoIuP9ymCisrulRWN7NYNzKSTMH5rx_vzA1BT4s7JnOPM2znxVEfB6AfcL67De6Fvk=\" rel=\"nofollow\" target=\"_blank\"><u>audrafriis@sambrown.com<\/u><\/a><br \/>(917) 519-9577<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZmU4NTBiNjQtMjY3Ny00MWM4LWJhMjUtZjc3YjhjNWZhOTA5LTEyMDQ0MTYtMjAyNS0wNS0wMi1lbg==\/tiny\/ALX-Oncology.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-845943","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of &hellip; Continue reading &quot;ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-02T12:04:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025\",\"datePublished\":\"2025-05-02T12:04:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/\"},\"wordCount\":210,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/\",\"name\":\"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=\",\"datePublished\":\"2025-05-02T12:04:42+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/","og_locale":"en_US","og_type":"article","og_title":"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., May 02, 2025 (GLOBE NEWSWIRE) &#8212; ALX Oncology Holdings Inc., (\u201cALX Oncology\u201d or the \u201cCompany\u201d) (Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives, today announced plans to report its first quarter 2025 financial results on Thursday, May 8th, 2025, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About ALX Oncology ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients\u2019 lives. ALX Oncology\u2019s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of &hellip; Continue reading \"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-02T12:04:42+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025","datePublished":"2025-05-02T12:04:42+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/"},"wordCount":210,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/","name":"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=","datePublished":"2025-05-02T12:04:42+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ0MzM2MiM2OTE3NTUwIzIxOTI4NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/alx-oncology-to-report-first-quarter-2025-financial-results-on-may-8-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"ALX Oncology to Report First Quarter 2025 Financial Results on May 8, 2025"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=845943"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/845943\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=845943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=845943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=845943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}